chidamide and Lymphoma

chidamide has been researched along with Lymphoma* in 1 studies

Reviews

1 review(s) available for chidamide and Lymphoma

Article	Year
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. Journal of medicinal chemistry, 2020, 11-12, Volume: 63, Issue:21 It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clinical development for oncology as well as other therapeutic indications. This Perspective reviews the biological and medicinal chemistry advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms. Topics: Anilides; Biological Products; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Isoenzymes; Lymphoma; Sulfhydryl Compounds	2020

Article

Year

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.

Journal of medicinal chemistry, 2020, 11-12, Volume: 63, Issue:21

It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clinical development for oncology as well as other therapeutic indications. This Perspective reviews the biological and medicinal chemistry advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.

Topics: Anilides; Biological Products; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Isoenzymes; Lymphoma; Sulfhydryl Compounds

2020